Amicus Therapeutics (FOLD) Misses Q3 EPS by 56c, Revenues Miss; Offers FY18 Revenue Outlook Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Amicus Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Updates
November 5, 2018 7:00 AM ESTU.S. Galafold® (Migalastat) Fabry Launch Tracking Significantly Ahead of Expectations- 100+ Patients Prescribed Galafold Since August Launch
3Q18 Global Galafold Net Product Sales of $20.6M Driven by Continued International Growth - 500+ International Fabry Patients Now on Galafold
Reaffirming Higher End of FY18 Revenue Guidance of $80M-$90M Balance Sheet Strength Sufficient to Fund Operations into at least 2021
Gene Therapy Pipeline Provides 14 New Programs and... More
